RECRUITING

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

Description

The purpose of this study is to learn what happens to MK-8527 in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to MK-8527 in the body when it is given to healthy participants and participants with mild and moderate hepatic (liver) impairment.

Conditions

Hepatic ImpairmentHealthy Participants
Talk to us

Related Conditions:

Hepatic ImpairmentHealthy Participants

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to learn what happens to MK-8527 in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to MK-8527 in the body when it is given to healthy participants and participants with mild and moderate hepatic (liver) impairment.

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants With Mild and Moderate Hepatic Impairment

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

Condition
Hepatic Impairment
Intervention / Treatment

-

Contacts and Locations

Chandler

Arizona Clinical Trials (0001), Chandler, Arizona, United States, 85225

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Is a continuous non-smoker or moderate smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing
  • * Has body mass index (BMI) ≥ 18.0 and ≤ 40.0 kg/m\^2
  • * Has a diagnosis of chronic, stable, hepatic insufficiency with features of cirrhosis due to any etiology
  • * Has mild or moderate hepatic impairment
  • * Is generally in good health with the exception of HI
  • * Has a history of cancer (malignancy)
  • * Has positive results for human immunodeficiency virus (HIV)
  • * Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing
  • * With the exception of HI, has a history or presence of clinically significant medical or psychiatric condition or disease
  • * Is positive for Hepatitis B Virus (HBV)
  • * Is positive for Hepatitis C Virus (HCV)

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Merck Sharp & Dohme LLC,

Medical Director, STUDY_DIRECTOR, Merck Sharp & Dohme LLC

Study Record Dates

2026-01-07